BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 25753670)

  • 1. Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy.
    Wojtkowiak-Szlachcic A; Taylor K; Stepniak-Konieczna E; Sznajder LJ; Mykowska A; Sroka J; Thornton CA; Sobczak K
    Nucleic Acids Res; 2015 Mar; 43(6):3318-31. PubMed ID: 25753670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy.
    Christou M; Wengel J; Sokratous K; Kyriacou K; Nikolaou G; Phylactou LA; Mastroyiannopoulos NP
    Nucleic Acid Ther; 2020 Apr; 30(2):80-93. PubMed ID: 31873063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.
    Yadava RS; Yu Q; Mandal M; Rigo F; Bennett CF; Mahadevan MS
    Hum Mol Genet; 2020 Jun; 29(9):1440-1453. PubMed ID: 32242217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced cytoplasmic MBNL1 is an early event in a brain-specific mouse model of myotonic dystrophy.
    Wang PY; Lin YM; Wang LH; Kuo TY; Cheng SJ; Wang GS
    Hum Mol Genet; 2017 Jun; 26(12):2247-2257. PubMed ID: 28369378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy.
    Leger AJ; Mosquea LM; Clayton NP; Wu IH; Weeden T; Nelson CA; Phillips L; Roberts E; Piepenhagen PA; Cheng SH; Wentworth BM
    Nucleic Acid Ther; 2013 Apr; 23(2):109-17. PubMed ID: 23308382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sense and Antisense DMPK RNA Foci Accumulate in DM1 Tissues during Development.
    Michel L; Huguet-Lachon A; Gourdon G
    PLoS One; 2015; 10(9):e0137620. PubMed ID: 26339785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy.
    Sobczak K; Wheeler TM; Wang W; Thornton CA
    Mol Ther; 2013 Feb; 21(2):380-7. PubMed ID: 23183533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1.
    Stepniak-Konieczna E; Konieczny P; Cywoniuk P; Dluzewska J; Sobczak K
    Nucleic Acids Res; 2020 Mar; 48(5):2531-2543. PubMed ID: 31965181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy.
    Ho TH; Savkur RS; Poulos MG; Mancini MA; Swanson MS; Cooper TA
    J Cell Sci; 2005 Jul; 118(Pt 13):2923-33. PubMed ID: 15961406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I.
    Zhang F; Bodycombe NE; Haskell KM; Sun YL; Wang ET; Morris CA; Jones LH; Wood LD; Pletcher MT
    Hum Mol Genet; 2017 Aug; 26(16):3056-3068. PubMed ID: 28535287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanded CUG repeats in
    van Cruchten RTP; Wieringa B; Wansink DG
    RNA; 2019 Apr; 25(4):481-495. PubMed ID: 30700578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models.
    González ÀL; Konieczny P; Llamusi B; Delgado-Pinar E; Borrell JI; Teixidó J; García-España E; Pérez-Alonso M; Estrada-Tejedor R; Artero R
    PLoS One; 2017; 12(6):e0178931. PubMed ID: 28582438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1.
    De Serres-Bérard T; Ait Benichou S; Jauvin D; Boutjdir M; Puymirat J; Chahine M
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A CTG repeat-selective chemical screen identifies microtubule inhibitors as selective modulators of toxic CUG RNA levels.
    Reddy K; Jenquin JR; McConnell OL; Cleary JD; Richardson JI; Pinto BS; Haerle MC; Delgado E; Planco L; Nakamori M; Wang ET; Berglund JA
    Proc Natl Acad Sci U S A; 2019 Oct; 116(42):20991-21000. PubMed ID: 31570586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptome Analysis Reveals Altered Inflammatory Pathway in an Inducible Glial Cell Model of Myotonic Dystrophy Type 1.
    Azotla-Vilchis CN; Sanchez-Celis D; Agonizantes-Juárez LE; Suárez-Sánchez R; Hernández-Hernández JM; Peña J; Vázquez-Santillán K; Leyva-García N; Ortega A; Maldonado V; Rangel C; Magaña JJ; Cisneros B; Hernández-Hernández O
    Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33530452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precise small-molecule cleavage of an r(CUG) repeat expansion in a myotonic dystrophy mouse model.
    Angelbello AJ; Rzuczek SG; Mckee KK; Chen JL; Olafson H; Cameron MD; Moss WN; Wang ET; Disney MD
    Proc Natl Acad Sci U S A; 2019 Apr; 116(16):7799-7804. PubMed ID: 30926669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting nuclear RNA for in vivo correction of myotonic dystrophy.
    Wheeler TM; Leger AJ; Pandey SK; MacLeod AR; Nakamori M; Cheng SH; Wentworth BM; Bennett CF; Thornton CA
    Nature; 2012 Aug; 488(7409):111-5. PubMed ID: 22859208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (CTG)n repeat-mediated dysregulation of MBNL1 and MBNL2 expression during myogenesis in DM1 occurs already at the myoblast stage.
    André LM; van Cruchten RTP; Willemse M; Wansink DG
    PLoS One; 2019; 14(5):e0217317. PubMed ID: 31116797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stabilization of expanded (CTG)•(CAG) repeats by antisense oligonucleotides.
    Nakamori M; Gourdon G; Thornton CA
    Mol Ther; 2011 Dec; 19(12):2222-7. PubMed ID: 21971425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HnRNP H inhibits nuclear export of mRNA containing expanded CUG repeats and a distal branch point sequence.
    Kim DH; Langlois MA; Lee KB; Riggs AD; Puymirat J; Rossi JJ
    Nucleic Acids Res; 2005; 33(12):3866-74. PubMed ID: 16027111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.